These biologic agents, mainly monoclonal antibodies, are aimed at crucial molecular pathways involved in asthma’s pathogenesis, such as interleukin-5 (IL-5), interleukin-4 (IL-4), interleukin-13 (IL-13), and immunoglobulin E (IgE, see Table 1) [1]. This evidence concerns the gene IL4 and asthma.